A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 289,106 shares of AKRO stock, worth $6.62 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
289,106
Previous 644,305 55.13%
Holding current value
$6.62 Million
Previous $15 Million 51.46%
% of portfolio
0.02%
Previous 0.04%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$17.76 - $31.18 $6.31 Million - $11.1 Million
-355,199 Reduced 55.13%
289,106 $7.3 Million
Q4 2023

Feb 14, 2024

BUY
$11.38 - $50.33 $6.89 Million - $30.5 Million
605,705 Added 1569.18%
644,305 $15 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $1.59 Million - $2.02 Million
38,600 New
38,600 $1.95 Million
Q2 2022

Aug 15, 2022

BUY
$8.0 - $15.01 $3.62 Million - $6.8 Million
453,000 Added 24.53%
2,300,000 $21.7 Million
Q1 2022

May 16, 2022

BUY
$12.97 - $22.26 $1.15 Million - $1.97 Million
88,499 Added 5.03%
1,847,000 $26.2 Million
Q4 2021

Feb 14, 2022

BUY
$19.87 - $26.24 $7.16 Million - $9.45 Million
360,101 Added 25.75%
1,758,501 $37.2 Million
Q3 2021

Nov 15, 2021

BUY
$18.65 - $25.46 $3.85 Million - $5.26 Million
206,700 Added 17.34%
1,398,400 $31.3 Million
Q2 2021

Aug 16, 2021

BUY
$24.81 - $32.35 $17 Million - $22.2 Million
685,203 Added 135.28%
1,191,700 $29.6 Million
Q1 2021

May 17, 2021

SELL
$24.04 - $34.19 $4.77 Million - $6.79 Million
-198,503 Reduced 28.16%
506,497 $14.7 Million
Q4 2020

Feb 16, 2021

BUY
$25.12 - $29.89 $14.1 Million - $16.8 Million
561,861 Added 392.53%
705,000 $18.2 Million
Q3 2020

Nov 16, 2020

SELL
$30.79 - $39.92 $9.3 Million - $12.1 Million
-301,893 Reduced 67.84%
143,139 $4.41 Million
Q2 2020

Aug 14, 2020

SELL
$19.25 - $26.76 $5.39 Million - $7.5 Million
-280,213 Reduced 38.64%
445,032 $11.1 Million
Q1 2020

May 15, 2020

BUY
$12.8 - $27.05 $6.39 Million - $13.5 Million
498,945 Added 220.48%
725,245 $15.4 Million
Q4 2019

Feb 14, 2020

BUY
$17.37 - $27.27 $2.08 Million - $3.26 Million
119,600 Added 112.09%
226,300 $5.02 Million
Q3 2019

Nov 15, 2019

BUY
$16.89 - $29.88 $1.3 Million - $2.29 Million
76,700 Added 255.67%
106,700 $2.43 Million
Q2 2019

Aug 14, 2019

BUY
$18.08 - $19.83 $542,400 - $594,900
30,000 New
30,000 $575,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.06B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.